Mechanisms of gefitinib-induced QT prolongation
Ling-Jun Jie,Yun-Da Li,He-Qiang Zhang,Liang Mao,Hua-Bin Xie,Fa-Guang Zhou,Tian-Li Zhou,Dong Xie,Jia-Le Lin,Gui-Yang Li,Bin-Ni Cai,Yan-Hui Zhang,Yan Wang
DOI: https://doi.org/10.1016/j.ejphar.2021.174441
IF: 5.195
2021-11-01
European Journal of Pharmacology
Abstract:Gefitinib, a tyrosine kinase inhibitor, was the first targeted therapy for non-small cell lung cancer (NSCLC). Gefitinib could block human Ether-à-go-go-Related Gene (hERG) channel, an important target in drug-induced long QT syndrome. However, it is unclear whether gefitinib could induce QT interval prolongation. Here, whole-cell patch-clamp technique was used for evaluating the effect of gefitinib on rapidly-activating delayed rectifier K<sup>+</sup> current (I<sub>Kr</sub>), slowly-activating delayed rectifier K<sup>+</sup> current (I<sub>Ks</sub>), transient outward potassium current (I<sub>to</sub>), inward rectifier K<sup>+</sup> current (I<sub>K1</sub>) and on action potentials in guinea pig ventricular myocytes. The Langendorff heart perfusion technique was used to determine drug effect on the ECG. Gefitinib depressed I<sub>Kr</sub> by binding to open and closed hERG channels in a concentration-dependent way (IC<sub>50:</sub> 1.91 μM). The inhibitory effect of gefitinib on wildtype hERG channels was reduced at the hERG mutants Y652A, S636A, F656V and S631A (IC<sub>50:</sub> 8.51, 13.97, 18.86, 32.99 μM), indicating that gefitinib is a pore inhibitor of hERG channels. In addition, gefitinib accelerated hERG channel inactivation and decreased channel steady-state inactivation. Gefitinib also decreased I<sub>Ks</sub> with IC<sub>50</sub> of 23.8 μM. Moreover, gefitinib increased action potential duration (APD) in guinea pig ventricular myocytes and the corrected QT interval (QTc) in isolated perfused guinea pig hearts in a concentration-dependent way (1-30 μM). These findings indicate that gefitinib could prolong QTc interval by potently blocking hERG channel, modulating kinetic properties of hERG channel. Partial block of KCNQ1/KCNE1 could also contribute to delayed repolarization and prolonged QT interval. Thus, caution should be taken when gefitinib is used for NSCLC treatment.
pharmacology & pharmacy